A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy

A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy

Abstract Background Immunotherapy has emerged as an efficient therapeutic approach for cancer management. However, stimulation of host immune system against cancer cells often fails to achieve promising clinical outcomes mainly owing to the immunosuppressive characteristics of the tumor microenviron...

Full description

Bibliographic Details
Main Authors: Amirhossein Bahreyni, Huitao Liu, Yasir Mohamud, Yuan Chao Xue, Yiyun Michelle Fan, Yizhuo Lyanne Zhang, Honglin Luo
Format: Article
Language:English
Published: BMC 2023-05-01
Series:BMC Medicine
Subjects:
Virotherapy
Immunotherapy
Chemotherapy
Coxsackievirus B3
Melittin
Immunogenic cell death
Online Access:https://doi.org/10.1186/s12916-023-02901-y

Internet

https://doi.org/10.1186/s12916-023-02901-y

Similar Items